Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
Absci official news RSS · 行业原文收录 · 来源发布：Wed Jun 24 2026 10:30:27 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:26 GMT+0000 (Coordinated Universal Time)
已保存的原文节选
Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval of two or three injections over six-month period First multiple ascending dose
以上为带出处的原文节选，完整内容请阅读原始链接。自动收录与主题分类不等于事实核验。